Recent News for ATNM - Actinium Pharmaceuticals, Inc.

Date Title
Feb 11 Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting
Feb 10 Actinium Announces Participation in BIO CEO & Investor Digital Conference
Jan 20 Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
Jan 13 Actinium, Astellas in research pact for radiotherapies
Jan 13 Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
Jan 2 Wall Street Breakfast: What Moved Markets
Dec 29 Actinium down 22% on independent data monitoring committee recommendation for Iomab-B trial
Dec 29 Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
Dec 9 Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should Know
Dec 9 Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit
Dec 8 Benzinga Global Small Cap Conference Day 1 Recap: Sorrento, Arcimoto And Much More
Dec 8 Actinium Pharmaceuticals rises 2% after seeing 67% ORR in first cohort in Actimab-A/venetoclax combination trial
Dec 8 Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH
Dec 7 Actinium's Iomab-B shows encouraging action in late-stage leukemia study
Dec 7 Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting
Dec 7 Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting
Dec 7 Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting
Dec 4 Actinium Pharmaceuticals: Our Bullish View Is Intact On Promising Early Stage Results
Dec 3 Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting
Dec 3 Is Actinium Pharmaceuticals (ATNM) A Good Stock To Buy Now?
Dec 2 Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know
Dec 1 Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Nov 29 The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Nov 23 Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
Nov 19 Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs
Back to the Main ATNM Page...